Dysplasia clinical trials at UCSF
3 in progress, 2 open to eligible people
Dysplasia is when cells look or act different from normal cells. UCSF is studying pre-existing antibodies to a viral vector and how they link to PKP2-associated ARVC progression. UCSF is testing a new therapy in adults with PKP2 mutations with increasing doses to check safety.
Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
open to eligible people ages 18-65
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
San Francisco, California and other locations
Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
open to eligible people ages 14-65
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
San Francisco, California and other locations
Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
Sorry, in progress, not accepting new patients
A Multi-Center Study in Patients Undergoing Total Hip Arthroplasty with the Smith+Nephew CATALYSTEM™ Primary Hip System. The purpose of the study is to assess safety and performance of the CATALYSTEM™ and to support product approval in global markets.
San Francisco, California and other locations